(ExoSCRT ¢â) ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í ¬Ú / ¬Ú¬Ý¬Ú ¬Ó¬ß¬Ö¬Ü¬Ý¬Ö¬ä¬à¬é¬ß¬í¬Ö ¬Ó¬Ö¬Ù¬Ú¬Ü¬å¬Ý¬í ¬Ú ¬ã¬á¬à¬ã¬à¬Ò¬í ¬á¬â¬Ú¬Ô¬à¬ä¬à¬Ó¬Ý¬Ö¬ß¬Ú¬ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬Û, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ú¬ç ¬Ú¬ç
(¬¡¬ä¬à¬á¬Ú¬é¬Ö¬ã¬Ü¬Ú¬Û ¬Õ¬Ö¬â¬Þ¬Ñ¬ä¬Ú¬ä) ¬µ¬Ý¬å¬é¬ê¬Ö¬ß¬Ú¬Ö ¬Õ¬Ö¬â¬Þ¬Ñ¬ä¬Ú¬ä¬Ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬Ú, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ö¬Û ¬Ó ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö ¬Ñ¬Ü¬ä¬Ú¬Ó¬ß¬à¬Ô¬à ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬Ñ ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í, ¬á¬à¬Ý¬å¬é¬Ö¬ß¬ß¬í¬Ö ¬Ú¬Ù ¬Ø¬Ú¬â¬à¬Ó¬í¬ç ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü.
(Skin Barrier) ¬ª¬ã¬á¬à¬Ý¬î¬Ù¬å¬Ö¬ä¬ã¬ñ ¬Õ¬Ý¬ñ ¬å¬ã¬Ú¬Ý¬Ö¬ß¬Ú¬ñ ¬Ú¬Ý¬Ú ¬å¬Ý¬å¬é¬ê¬Ö¬ß¬Ú¬ñ ¬Ü¬à¬Ø¬ß¬à¬Ô¬à ¬Ò¬Ñ¬â¬î¬Ö¬â¬Ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬Ú, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ö¬Û ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í, ¬á¬à¬Ý¬å¬é¬Ö¬ß¬ß¬í¬Ö ¬Ú¬Ù ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü, ¬Ó ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö ¬Ñ¬Ü¬ä¬Ú¬Ó¬ß¬à¬Ô¬à ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬Ñ.
(¬³¬å¬Ò¬Ý¬Ú¬Þ¬Ñ¬è¬Ú¬à¬ß¬ß¬Ñ¬ñ ¬ã¬å¬ê¬Ü¬Ñ) ¬Þ¬Ö¬ä¬à¬Õ¬à¬Þ ¬Ý¬Ú¬à¬æ¬Ú¬Ý¬Ú¬Ù¬Ñ¬è¬Ú¬Ú ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ
(Bexosome-Volumizing) ¬¬¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ñ¬ñ ¬ã¬Ñ¬á¬à¬Ô¬Ö¬ß¬Ú¬ß ¬Ú ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬å ¬Ó ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö ¬Ñ¬Ü¬ä¬Ú¬Ó¬ß¬í¬ç ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬à¬Ó
(¬¿¬Ü¬Ù¬à¬ã¬à¬Þ¬Ñ ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬â¬à¬Ù¬í) ¬¬¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬Ñ¬ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ñ¬ñ ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬å, ¬á¬à¬Ý¬å¬é¬Ö¬ß¬ß¬å¬ð ¬Ú¬Ù ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬â¬à¬Ù¬í, ¬Ó ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö ¬Ñ¬Ü¬ä¬Ú¬Ó¬ß¬à¬Ô¬à ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬Ñ
(Cell Tweet ¢â) ¬¬¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬Ñ¬ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ ¬Õ¬Ý¬ñ ¬å¬Ý¬å¬é¬ê¬Ö¬ß¬Ú¬ñ ¬å¬Ó¬Ý¬Ñ¬Ø¬ß¬Ö¬ß¬Ú¬ñ ¬Ü¬à¬Ø¬Ú ¬Ú ¬Ù¬å¬Õ¬Ñ
(¬¿¬Ü¬Ù¬à¬ã¬à¬Þ¬ß¬í¬Û ¬ß¬Ñ¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î) ¬³¬ä¬Ñ¬Ò¬Ú¬Ý¬Ú¬Ù¬Ú¬â¬à¬Ó¬Ñ¬ß¬ß¬Ñ¬ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬ß¬à¬Ô¬à ¬ß¬Ñ¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬ñ
(Exomage ¢â -Itching) ¬¯¬à¬Ó¬à¬Ö ¬Ú¬ã¬á¬à¬Ý¬î¬Ù¬à¬Ó¬Ñ¬ß¬Ú¬Ö ¬ß¬Ñ¬Ò¬à¬â¬à¬Ó ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ú¬ç ¬á¬à¬Ý¬å¬é¬Ö¬ß¬ß¬í¬Ö ¬Ú¬Ù ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í
(¬¿¬Ü¬Ù¬à¬ã¬à¬Þ¬ß¬Ñ¬ñ ¬Ü¬à¬ã¬Þ¬Ö¬ä¬Ú¬Ü¬Ñ) ¬¬¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬Ñ¬ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ ¬Õ¬Ý¬ñ ¬à¬ä¬Ò¬Ö¬Ý¬Ú¬Ó¬Ñ¬ß¬Ú¬ñ ¬Ü¬à¬Ø¬Ú, ¬å¬Ý¬å¬é¬ê¬Ö¬ß¬Ú¬ñ ¬Þ¬à¬â¬ë¬Ú¬ß ¬Ú¬Ý¬Ú ¬â¬Ö¬Ô¬Ö¬ß¬Ö¬â¬Ñ¬è¬Ú¬Ú, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ñ¬ñ ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í, ¬Ú¬Ù¬Ó¬Ý¬Ö¬é¬Ö¬ß¬ß¬í¬Ö ¬Ú¬Ù ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü [Worldwide Exclusive License]
(¬¿¬Ü¬Ù¬à¬ã¬à¬Þ¬Ñ ¬Ü¬à¬ã¬Þ¬Ö¬ä¬Ú¬Ü¬Ñ) ¬¬¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬Ñ¬ñ ¬Ü¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ñ¬ñ ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í, ¬Ú¬Ù¬Ó¬Ý¬Ö¬é¬Ö¬ß¬ß¬í¬Ö ¬Ú¬Ù ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬Õ¬Ý¬ñ ¬à¬ä¬Ò¬Ö¬Ý¬Ú¬Ó¬Ñ¬ß¬Ú¬ñ ¬Ü¬à¬Ø¬Ú, ¬á¬â¬à¬ä¬Ú¬Ó ¬Þ¬à¬â¬ë¬Ú¬ß ¬Ú¬Ý¬Ú ¬â¬Ö¬Ô¬Ö¬ß¬Ö¬â¬Ñ¬è¬Ú¬Ú [Worldwide Exclusive License]
(¬¿¬Ü¬Ù¬à¬ã¬à¬Þ¬Ñ ¬Ü¬à¬ã¬Þ¬Ö¬ä¬Ú¬Ü¬Ñ) ¬¬¬à¬Þ¬á¬à¬Ù¬Ú¬è¬Ú¬ñ ¬Õ¬Ý¬ñ ¬Ú¬ß¬Õ¬å¬Ü¬è¬Ú¬Ú ¬Õ¬Ú¬æ¬æ¬Ö¬â¬Ö¬ß¬è¬Ú¬â¬à¬Ó¬Ü¬Ú ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ö¬Û ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬Ö ¬Ü¬Ý¬Ö¬ä¬Ü¬Ú, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ö¬Û ¬Ñ¬Õ¬Ú¬á¬à¬è¬Ú¬ä¬í, ¬â¬Ö¬Ô¬Ö¬ß¬Ö¬â¬Ñ¬è¬Ú¬Ú ¬Ø¬Ú¬â¬à¬Ó¬à¬Û ¬ä¬Ü¬Ñ¬ß¬Ú ¬Ú ¬à¬ä¬Ò¬Ö¬Ý¬Ú¬Ó¬Ñ¬ß¬Ú¬ñ ¬Ü¬à¬Ø¬Ú ¬Ú¬Ý¬Ú ¬å¬Ý¬å¬é¬ê¬Ö¬ß¬Ú¬ñ ¬Þ¬à¬â¬ë¬Ú¬ß [Worldwide Exclusive License]
(ASCE+¢â) ¬¡¬ß¬ä¬Ú¬à¬Ü¬ã¬Ú¬Õ¬Ñ¬ß¬ä¬ß¬í¬Ö ¬Õ¬à¬Ò¬Ñ¬Ó¬Ü¬Ú, ¬Ü¬à¬ä¬à¬â¬í¬Ö ¬á¬â¬à¬Ú¬Ù¬Ó¬à¬Õ¬ñ¬ä¬ã¬ñ ¬ß¬Ñ ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬Ü¬Ñ¬ç, ¬Ó¬Ü¬Ý¬ð¬é¬Ñ¬ð¬ä ¬Ó ¬ã¬Ö¬Ò¬ñ ¬Ù¬Ñ¬Þ¬à¬â¬à¬Ø¬Ö¬ß¬ß¬í¬Ö ¬Õ¬Ö¬Û¬ã¬ä¬Ó¬Ú¬ñ, ¬Ñ ¬ä¬Ñ¬Ü¬Ø¬Ö ¬Ú¬ç ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬à¬ã¬ä¬î.
¬Á¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ ¬á¬â¬à¬Õ¬å¬Ü¬ä¬à¬Þ ¬ã¬ß¬Ú¬Ø¬Ö¬ß¬Ú¬ñ ¬ï¬Ü¬ã¬á¬â¬Ö¬ã¬ã¬Ú¬Ú ¬æ¬Ú¬Ò¬â¬Ú¬Ý¬Ý¬ñ¬â¬ß¬í¬ç ¬Ó¬Ö¬ë¬Ö¬ã¬ä¬Ó, ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ñ¬ë¬Ú¬ç ¬æ¬Ý¬ð¬à¬â¬à¬ã¬à¬Þ¬í ¬à¬ä ¬à¬Ò¬â¬Ñ¬Ù¬à¬Ó¬Ñ¬ß¬Ú¬ñ ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬Ó ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬à¬Û ¬æ¬à¬â¬Þ¬Ö.
(ASCE+) ¬±¬â¬à¬ä¬Ú¬Ó¬à¬â¬Ö¬é¬Ú¬ñ, ¬Ú¬ß¬Ô¬Ú¬Ò¬Ú¬â¬à¬Ó¬Ñ¬ß¬Ú¬Ö, ¬å¬Ý¬å¬é¬ê¬Ö¬ß¬Ú¬Ö ¬Ú¬Ý¬Ú ¬Ý¬Ö¬é¬Ö¬ß¬Ú¬Ö ¬Ý¬Ú¬é¬Ú¬ß¬à¬Ü, ¬Ü¬à¬ä¬à¬â¬í¬Ö ¬Ó¬Ü¬Ý¬ð¬é¬Ñ¬ð¬ä ¬Ó ¬ã¬Ö¬Ò¬ñ ¬Ù¬Ñ¬Þ¬à¬â¬à¬Ù¬Ü¬å ¬Ý¬Ú¬é¬Ú¬ß¬à¬Ü ¬à¬ä ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü, ¬Ñ ¬ä¬Ñ¬Ü¬Ø¬Ö ¬Ú¬ç ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬à¬ã¬ä¬î.